

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

Long-term Antidepressant Prescribing in General Practice

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024051
Article Type:	Research
Date Submitted by the Author:	19-May-2018
Complete List of Authors:	Verhaak, Peter; Netherlands Institute of Health Services Research; Universitair Medisch Centrum Groningen, general practice de Beurs, Derek; Netherlands Institute of Health Services Research Spreeuwenberg, Peter; Netherlands Institute of Health Services Research
Keywords:	PRIMARY CARE, Anxiety disorders < PSYCHIATRY, Depression & mood disorders < PSYCHIATRY

 SCHOLARONE™
Manuscripts

Peer review only

Long-term Antidepressant Prescribing in General Practice

Article category: Epidemiology

Verhaak PFM¹, Beurs DP² de, Spreeuwenberg P²

¹ Netherlands institute of health services research (NIVEL), Utrecht, the Netherlands

University of Groningen, University Medical Center Groningen, Department of General Practice, Groningen, the Netherlands

² Netherlands institute of health services research, Utrecht, the Netherlands

Corresponding author:

Prof. dr P. F. M. Verhaak

Netherlands institute of health services research (NIVEL)

P.O. Box 1568

3500 BN Utrecht

The Netherlands

p.verhaak@nivel.nl

What is already known

- Antidepressant use increased considerably the past twenty years
- This increase was among others attributed to longer continuation of antidepressant treatment

What this study adds

- Of the patients prescribed an antidepressant in 2011, treatment was chronic in 42% during at least four following years
- Patients aged 45–64 years had the highest odds of being prescribed antidepressants in the long term.
- There is substantial practice variation in chronic antidepressant prescribing.

Abstract

Objectives. Antidepressant prescribing almost doubled in the Netherlands between 1996 and 2012, which could be accounted for by longer continuation after the first prescription. This might be problematic given a growing concern of large-scale antidepressant dependence. We aimed to assess the extent and determinants of chronic antidepressant prescribing. We hypothesize a relatively large prevalence of chronic (> 2 years) prescription.

Setting. 189 General practices in the Netherlands

Participants. 326,025 patients with valid prescription data for all five years of the study

Outcome measures. Primary outcome measure: the number of patients (N) receiving at least four antidepressant prescriptions in 2011, as well as during each of the four subsequent years. Secondary outcome measure: the above, but specified for Selective Serotonin Reuptake Inhibitors and for Tricyclic Antidepressants

Results. Antidepressants were prescribed to almost 7% of our 326,025 participants each year. They were prescribed for depression (38%), for anxiety (17%), other psychological disorders (20%) and non-psychological indications (25%). Antidepressants were prescribed in all five years to the 42% of the population who had at least four prescriptions dispensed in 2011. Chronic prescribing was higher among women than men, for those aged 45–64 years than for those aged >65 years and for those treated for depression or anxiety than for non-psychological indications (e.g., neuropathic pain). Chronic prescribing also varied markedly among general practices.

Conclusion. Chronic antidepressant use is common not only for depression but also for anxiety and non-psychological diagnoses. Once antidepressants have been prescribed, general practitioners and other prescribers should be aware of the risks associated with long-term use and should provide annual monitoring of the continued need for therapy.

Strengths and limitations of the study

- Strength: Large database, largely representative for Dutch population
- Strength: Routinely collected prescription data, reliable because needed for delivery by pharmacist
- Limitation: Morbidity data, needed for prescription *indication*, are dependent on coding by GP

INTRODUCTION

Antidepressants are recommended for the treatment of both major depression and anxiety disorders in most clinical guidelines. Based on evidence that they are more efficacious than placebo in adults with major depressive disorder (1), antidepressants were used by more than 12% of the adult US population in 2013, with the prevalence in women being approximately double that in men, and increasing with age (2). However, antidepressants are also prescribed off-label for disorders other than depression, most often in nursing homes and for older populations, with evidence supporting off-label use available in Dutch, UK, Swedish, Canadian and US populations (3–7). In the Netherlands, selective serotonin reuptake inhibitors (SSRIs) have typically been prescribed off-label for other psychological problems, while tricyclic antidepressants (TCAs) have tended to be preferred for pain disorders (3).

Dutch guidelines for the treatment of depression in general practice initially recommend watchful waiting and non-medical therapy, except for comparably rare presentations with suicidal ideation or psychosis. If symptoms persist, antidepressant medication can be considered if a depressive disorder is present, but not merely for the presence of depressive symptoms (8). According to the Dutch College of General Practitioners, psychopharmacological agents should not be used to treat anxiety symptoms, but they are considered to have efficacy for anxiety disorders (9). Despite this cautious approach, the prevalence of antidepressant prescribing almost doubled between 1996 and 2012 in the Netherlands (10).

In the 1990s, there was an increase in the prevalence and incidence of SSRI use, with more patients starting SSRIs and receiving antidepressant therapy for longer durations (11–16). An explanation for this increase in antidepressant prescribing might, therefore, be longer continuation after initial treatment. For example, Mars et al. (14) reported that the incidence of antidepressant prescriptions was stable between 1995 and 2011, but that the prevalence

1
2
3 more than doubled in the same period. In the Netherlands, Noordam et al. (10) showed the
4 same trends between 1996 and 2012. Given that equal numbers start therapy each year, but
5 the total number of users increases, the increase in prevalence might reflect longer
6 continuation of therapy.
7
8
9

10
11 Long-term antidepressant use has been reported in several studies that have used primary care
12 databases. In a recent Dutch study, antidepressants were used long-term (>15 months) by
13 30% and 44% in the periods 1995–2005 and 2005–2015, respectively (17). In a study of a
14 primary care database from Scotland, 40% of patients received SSRIs for longer than 180
15 days, and it was shown that practice variation accounted for most of the differences in
16 prescribing durations (18). In UK general practice, it has been reported that the mean
17 durations of antidepressant treatment were 4.8 years for depression, 7.4 years for anxiety and
18 5 years for pain (19). Read et al. also reported that 52% of a New Zealand sample continued
19 antidepressant treatment for three or more years, with this proportion increasing with age
20 (20), while Ambresin et al. reported that therapy was continued for more than 2 years in 47%
21 of antidepressant users. However, Sihvo (12) reported that only 14% of antidepressant users
22 in Finland continued therapy for more than two years. The results of an Australian study were
23 consistent with this latter finding, showing that 50% and 61% of new antidepressant users
24 had discontinued therapy within 6 and 12 months, respectively, and that only 20% had
25 continued therapy at three years. Receiving psychological or psychiatric care was associated
26 with longer antidepressant use, while the presence of either cancer or multiple morbidities
27 was associated with an increased likelihood of shorter treatment duration (21).
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 Little is known about the factors associated with long-term antidepressant use. Moreover,
50 although current Dutch guidelines recommend stopping treatment six months after remission
51 (9), they are not explicit about how to stop or about when long-term continuation is
52 appropriate. Regular monitoring and medication reviews are also recommended when
53
54
55
56
57
58
59
60

1
2
3 prescribing continues in the long term. Overall, the current real-world situation raises many
4
5 questions about the appropriateness of the current guidelines for clinical practice. Therefore,
6
7 we aimed to assess the extent of chronic antidepressant prescribing and to evaluate the
8
9 determinants of that chronic prescribing. Our main research questions were what proportion
10
11 of patients were prescribed antidepressants continuously during a five-year period and what
12
13 predicted long-term prescribing? We also wanted to answer four specific sub-questions: (1)
14
15 What proportions of patients continue therapy for more than two, three and four years? (2)
16
17 Are there differences in long-term prescribing by sex and age? (3) Are there differences in
18
19 long-term prescribing by the indication for antidepressant prescribing? and (4) Are there
20
21 differences in long-term prescribing between SSRIs and TCAs?
22
23
24
25
26

27 **METHOD**

28 **Study design and participants**

29
30
31 This was a cross-sectional observational study based on the data obtained in the NIVEL
32
33 Primary Care Database (NPCD). Participants were all patients aged 18 years and older,
34
35 registered in Dutch general practices participating in the NPCD.
36
37
38

39 **NIVEL Database**

40
41
42 Data were obtained from the NPCD. This database contains routinely collected data on
43
44 symptoms, diagnoses, medications and laboratory results related to the consultations for
45
46 patients from 367–519 general practices (the number of participating practices each year
47
48 varied) in the Netherlands. All non-institutionalised inhabitants of the Netherlands are
49
50 registered at a general practice, and the general practices and patient populations in the
51
52 NPCD have proven representativeness for wider Dutch society, although group practices are
53
54 somewhat overrepresented. For this study, we used data for adult patients aged 18 years and
55
56
57
58
59
60

1
2
3 older, covering the period 2011–2015.
4

5 ***Patient and Public involvement***

6
7
8 The data collection was approved by our institutional review board, who waived the need to
9
10 obtain specific consent. The study was conducted in accordance with the requirements of the
11
12 Helsinki Declaration. Patients in participating practices are informed about participation of
13
14 the practice in NPCD with an opportunity for opting out.
15

16 **Data**

17 ***Prescriptions***

18
19
20 Each medication prescription, including repeat prescriptions, were recorded by date and code
21
22 based on the Anatomical Therapeutic Chemical Classification System (i.e., ATC codes). The
23
24 following codes for antidepressants were included: N06AA (TCA), N06AB (SSRI), N06AF
25
26 (non-selective monoamine oxidase inhibitors [MAOI]), N06AG (type A MAOI) and N06AX
27
28 (other antidepressants).
29
30
31

32 ***Diagnosis***

33
34
35 Symptoms and diagnoses related to a given prescription were classified according to the
36
37 International Classification of Primary Care (22), using the P.xxxx codes for psychological
38
39 symptoms and disorders. Codes P03 (depressive symptom) and P76 (depressive disorder)
40
41 were taken to mean ‘depression’, while codes P01 (feeling nervous) and P74 (anxiety
42
43 disorder) were taken to mean ‘anxiety’. Codes not in Chapter P were recorded as somatic
44
45 symptoms and diagnoses.
46
47

48 ***Prevalence of antidepressant prescription***

49
50
51 For each year, we calculated the number of patients (N) prescribed an antidepressant, SSRI or
52
53 TCA and whether the prescription was linked to a record of depression, anxiety or other
54
55 disorder (non-psychological/somatic). We recorded the number of patients with a prescription
56
57
58
59

per 1000 patient-years, linked to age and gender, within a certain year. These data allow for extrapolation to the Dutch population based on a yearly weighted population at risk in the NPCD, which varied annually from 1,087,395 to 1,641,806 patient-years.

Long-term use

To calculate the numbers of patients using prescriptions for several years, the data for different years were merged to give the number of patients with a recorded antidepressant prescription and diagnosis of depression in each of the study years (i.e., 2011, 2012, 2013, 2014 and 2015). Merging data for the five subsequent years resulted in a loss of cases, because the NIVEL database did not include all practices or patients in some years.

Statistical Analysis

We use multilevel logistic regression with patients clustered by general practice. The models were then analysed in MLwiN 2.30 (23), using with the options 'PQL' and 'second order' ('first order' was used if the model failed to converge), and 'constrained level one variance'.

Outcome measures

The main outcome measure was the number of patients (N) receiving at least four antidepressant prescriptions in 2011, as well as during each of the four subsequent years. We assumed that receiving four or more prescriptions in one year was consistent with chronic use, based on the common Dutch practice to prescribe antidepressants on repeat prescriptions for three-month periods.

Independent variables

At Level 1, we controlled for variation at the practice level. At Level 2, the patient level, we considered age in 2011, sex and diagnosis associated with the prescription (i.e., depression, anxiety or somatic problem)

RESULTS

The results about long-term antidepressants use are based on data for 326,025 patients from 189 practices with valid prescription data for all five years of the study. In 2011, antidepressants were prescribed to $\pm 71/1000$ registered patients aged ≥ 18 years. About two-thirds of the prescriptions were for women and about one-third were for men. By age, antidepressants were prescribed to 30%, 45% and 25% of those aged 18–44 years, 45–64 years and >65 years, respectively.

Of the antidepressants prescribed, SSRIs and TCAs accounted for 52% and 28%, respectively. Overall, 38% were prescribed for depression, 17% for anxiety, 20% for other psychological diagnoses and 25% for somatic indications. SSRIs were more frequently prescribed for depression (47%) and anxiety (23%), while TCAs tended to be prescribed frequently for somatic disorders (44%) or other psychological disorders (21%). The main somatic indications for TCAs were generalised pain (1.7%), lumbago (2.5%), low backpain with radiation (2.5%), headache (2.7%), tension headache (2%), neuropathy (4.8%), sleeping problems (4.1%) and type 2 diabetes mellitus (1.5%).

The data for the proportions of patients who continued to be prescribed antidepressants in each year after 2011 are summarised in Figure 1 and Table 1.

Here figure 1

Of those who received at least four prescriptions in 2011, we found that 65% were still receiving at least four prescriptions per year at two years and that 58% were still receiving them at three years. However, only 42% of patients received antidepressants through each year from 2011 to 2015; by SSRI and TCA use, this was 38% and 35%, respectively (Figure 1). The odds for receiving antidepressants over five consecutive years based on patients' characteristics are shown in Table 1.

Table 1. Odds for Receiving an Antidepressant for Each Year between 2011 and 2015 after Receiving the First Prescription in 2011

Variable	Coefficient	SE	p-value	OR	95% CI	
Sex (ref = male)						
Female	0.1400	0.0409	0.0006	1.15	1.06	1.25
Age (ref = 65+ years)						
19–44	-0.1161	0.0541	0.0320	0.89	0.80	0.99
45–64	0.2320	0.0476	0.0000	1.26	1.15	1.38
Disorder (ref = no anxiety)						
Anxiety	0.3196	0.0558	0.0000	1.38	1.23	1.54
Depression	0.3224	0.0488	0.0000	1.38	1.25	1.52
Somatic disorder	0.0153	0.0565	0.7864	1.02	0.91	1.13
Practice variance	6.763	0.8653				
ICC	0.67					
Constant	-4.2012	0.2276				

Abbreviations: CI, confidence interval; ICC, intraclass correlation coefficient; OR, odds ratio; SE, standard error

Specifically, the odds were higher for women than for men, for patients aged 45–65 years and for a diagnosis of anxiety or depression. However, there was substantial practice variation, meaning that the proportions were even larger in some practices but much smaller in others. Tables 1 and 2 in the appendix show similar patterns for SSRIs and TCAs analysed separately, though with some exceptions. A diagnosis of anxiety, for example, did not affect long-term SSRI prescribing. Also, sex and older age affected long-term TCA prescribing, but indication did not.

DISCUSSION

Antidepressants were prescribed to almost 7% of the general practice population in this study.

1
2
3 The main indication was for depression (38%), but anxiety (17%), other psychological
4 disorders (20%) and non-psychological indications, mostly pain related (25%), were frequent.
5
6 Interestingly, nearly half of the population (42%) received antidepressants throughout all five
7 years of the study. The odds of long-term use were higher for women than for men, for those
8 aged 45–64 years than for those aged ≥ 65 years and for those with psychological indications
9 than for those with non-psychological indications. However, long-term prescribing habits
10 varied markedly among practices.
11
12

13
14
15
16
17
18 Consistent with our results, Huijbregts et al. (17) reported that about 44% of antidepressant
19 use was long term (defined as >15 months) based on one region in the Netherlands. In our
20 larger nationwide population, with a much stricter definition of long-term use as five years of
21 continuous receipt of four antidepressant prescriptions a year, 42% used antidepressants
22 chronically. We also found the same risk factors for long-term use, with female sex, older
23 age, and having a diagnosis of anxiety or depression being most important. However, in
24 contrast with their data, we found that the group aged 45–64 years was at higher risk than the
25 group aged ≥ 65 years.
26
27
28
29
30
31
32
33
34
35

36 Antidepressant medication use is a prominent topic of discussion in society. Opponents of
37 their widespread use, such as Gøtzsche (25) and Greenberg (26), point to the lack of efficacy
38 and the possible harms of long-term use. By contrast, proponents, such as Young and Crace
39 (27), consider psychiatric drugs to be as beneficial as other medical treatments and argue that
40 concerns about long-term use are overinflated. So, just how harmful is antidepressant use in
41 the long term? We know that antidepressant use is now on a large scale, partly for depression
42 and anxiety, but also for other psychological and non-psychological indications. This is
43 important to understand because antidepressants have only demonstrated slight effectiveness
44 for the treatment of depression and anxiety (28), and have unknown efficacy for those other
45 disorders. Although some patients will benefit from long-term use (29), at best, such use may
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 be unhelpful to many patients. Indeed, there is no conclusive evidence about the safety of
4 antidepressants over years, and Andrews et al. even claim that such use will generally do
5 more harm than good by disrupting key adaptive processes regulated by serotonin (30). Harm
6 may also be expected among older antidepressant users who are at risk of polypharmacy;
7 antidepressant use, for example, has an important negative impact on the Drug Burden Index,
8 an indicator of the cholinergic and sedative stress imposed by medication (31).
9
10
11
12
13
14
15

16 At first glance, general practitioners (GPs) might view antidepressant treatment as a good
17 initial therapy that is in the patient's interest. Despite the potential risks, and perhaps because
18 of the lack of clear evidence of harm, or reports of continuation problems, the option of long-
19 term use also remains acceptable (32). This is compounded by the fact that, when patients
20 have benefitted from relief of depressive symptoms, they often become reluctant to stop
21 therapy for fear of becoming depressed again (33). Therefore, large groups of patients with
22 single episodes of low severity depression, who probably received effective antidepressant
23 therapy in the beginning, progress to long-term use with less clearly defined benefits.
24
25
26
27
28
29
30
31
32
33

34 A way to prevent unnecessary long-term antidepressant use might be to institute annual
35 medication reviews. This issue is especially pertinent given that proactive medication reviews
36 have been reported to become increasingly sparse the longer antidepressants have been
37 prescribed, especially when not for an overt mental health reason (34). Medication reviews
38 may be a practice characteristic that explains the substantial variation among practices in our
39 analyses. As proven in other studies, medication reviews may be routine in some practices,
40 leading to reduced long-term antidepressant use, but may non-existent in other practices, with
41 opposing results (35). The lack of evidence on how best to discontinue medication makes this
42 between-practice variation unsurprising. New initiatives, such as the introduction of tapering
43 strips (36) or the continuous monitoring of patients who discontinue antidepressants, could
44 offer new insights and help develop recommendations for GPs to help patients stop treatment
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 when it is no longer needed. Developing a consensus on how to discontinue antidepressants
4 in general practice could reduce practice variation and decrease the proportions of patients
5 who continue to take antidepressants beyond the required period for acute treatment and
6 stabilization.
7
8
9
10

11 **Limitations**

12
13
14 Although prescription data were available of 1–2 million patients, substantial numbers were
15 lost by merging the data over several years (e.g., some practices were not part of the NPCD
16 for the full period and some patients were not registered for the full period). Therefore, the
17 final analyses were conducted on 326,025 cases from 189 practices. This final sample
18 included more patients aged >45 years and fewer men compared with the original database,
19 so may have not been truly representative of the Dutch population. Morbidity data were also
20 highly dependent on the coding registered by the GP. It is well known that GP variations in
21 diagnosis are large and that sensitivity can be suboptimal (24). However, the antidepressant
22 prescribing data were not dependent on the morbidity coding, which is a major strength.
23
24
25
26
27
28
29
30
31
32
33

34 **Conclusions**

35
36
37 Chronic antidepressant use was common in this cohort, with 42% of patients prescribed
38 antidepressants in 2011 continuing to use them at five years. Although the initial prescribing
39 of antidepressants might have become stable, patients continue to take their prescriptions for
40 many years, though with considerable variation in this trend between practices. It was
41 noteworthy that depression was not the main indication for antidepressant prescription, with a
42 quarter of prescriptions being for non-psychological indications and a fifth being for anxiety.
43
44
45 Therefore, we conclude that the high levels of antidepressant use can only partly be attributed
46 to depression, with the main issue appearing to be an increase in chronic usage after initial
47 prescribing. GPs and other prescribers should be aware of the risks of long-term
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

antidepressant use and ensure annual monitoring to reduce unnecessary prescribing.

For peer review only

Acknowledgements

We thank Dr Robert Sykes (www.doctored.org.uk) for providing editorial services.

Author contributions

Peter Verhaak conceived the concept, analysed the data and wrote the paper. Derek de Beurs discussed the concept and commented on all drafts. Peter Spreeuwenberg performed the multilevel analysis and commented on all drafts.

Conflicts of interest

None

Funding

All authors are appointed by the Netherlands Institute of Health Services Research.

Transparency declaration

The lead author (PV) affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Ethical issues

The data collection was approved by our institutional review board, who waived the need to obtain specific consent. The study was conducted in accordance with the requirements of the Helsinki Declaration. Patients in participating practices were informed about the practice's participation in NPCD and were free to opt out.

References

1. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *The Lancet*. 2018;dx.doi.org/10.1016/50140-6736(17)32802-7.
2. Moore TJ, Mattison DR. Adult Utilization of Psychiatric Drugs and Differences by Sex, Age, and Race. *JAMA Intern Med*. 2017;177(2):274-5.
3. Aarts N, Noordam R, Hofman A, Tiemeier H, Stricker BH, Visser LE. Self-reported indications for antidepressant use in a population-based cohort of middle-aged and elderly. *Int J Clin Pharm*. 2016;38(5):1311-7.
4. Hanlon JT, Wang X, Castle NG, Stone RA, Handler SM, Semla TP, et al. Potential underuse, overuse, and inappropriate use of antidepressants in older veteran nursing home residents. *Journal of the American Geriatrics Society*. 2011;59(8):1412-20.
5. Harris T, Carey IM, Shah SM, DeWilde S, Cook DG. Antidepressant prescribing in older primary care patients in community and care home settings in England and Wales. *J Am Med Dir Assoc*. 2012;13(1):41-7.
6. Midlov P, Andersson M, Ostgren CJ, Molstad S. Depression and use of antidepressants in Swedish nursing homes: a 12-month follow-up study. *International psychogeriatrics / IPA*. 2014;26(4):669-75.
7. Wong J, Motulsky A, Abrahamowicz M, Egualé T, Buckeridge DL, Tamblyn R. Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system. *BMJ*. 2017;356:j603.
8. Weel-Baumgarten EMv, Gelderen MGv, Grundmeijer HGLM, Licht-Strunk E, Marwijk HWJv, Rijswijk HCAMv, et al. NHG-Standaard Depressie (tweede herziening). Huisarts

- 1
2
3 & Wetenschap. 2012;55(6):252-9.
4
5
6 9. Hassink-Franke L, Terluin B, Heest Fv, Hekman J, Marwijk Hv, Avendonk Mv. NHG-
7
8 Standaard Angst (tweede herziening). Utrecht: Nederlands Huisarts Genootschap, 2012.
9
10
11 10. Noordam R, Aarts N, Verhamme KM, Sturkenboom MC, Stricker BH, Visser LE.
12
13 Prescription and indication trends of antidepressant drugs in the Netherlands between
14
15 1996 and 2012: a dynamic population-based study. *European journal of clinical*
16
17 *pharmacology*. 2015;71(3):369-75.
18
19
20 11. Meijer WE, Heerdink ER, Leufkens HG, Herings RM, Egberts AC, Nolen WA.
21
22 Incidence and determinants of long-term use of antidepressants. *European journal of*
23
24 *clinical pharmacology*. 2004;60(1):57-61.
25
26
27 12. Sihvo S, Wahlbeck K, McCallum A, Sevon T, Arffman M, Haukka J, et al. Increase in
28
29 the duration of antidepressant treatment from 1994 to 2003: a nationwide population-
30
31 based study from Finland. *Pharmacoepidemiol Drug Saf*. 2010;19(11):1186-93.
32
33
34 13. Mojtabai R, Olfson M. National trends in long-term use of antidepressant medications:
35
36 results from the U.S. National Health and Nutrition Examination Survey. *The Journal of*
37
38 *clinical psychiatry*. 2014;75(2):169-77.
39
40
41 14. Mars B, Heron J, Kessler D, Davies NM, Martin RM, Thomas KH, et al. Influences on
42
43 antidepressant prescribing trends in the UK: 1995-2011. *Soc Psychiatry Psychiatr*
44
45 *Epidemiol*. 2017;52(2):193-200.
46
47
48 15. Moore M, Yuen HM, Dunn N, Mullee MA, Maskell J, Kendrick T. Explaining the rise in
49
50 antidepressant prescribing: a descriptive study using the general practice research
51
52 database. *BMJ*. 2009;339:b3999.
53
54
55 16. Lockhart P, Guthrie B. Trends in primary care antidepressant prescribing 1995-2007: a
56
57 longitudinal population database analysis. *Br J Gen Pract*. 2011;61(590):e565-72.
58
59
60

- 1
2
3 17. Huijbregts KM, Hoogendoorn A, Slottje P, van Balkom A, Batelaan NM. Long-Term
4 and Short-Term Antidepressant Use in General Practice: Data from a Large Cohort in the
5 Netherlands. *Psychother Psychosom*. 2017;86(6):362-9.
6
7
- 8
9 18. Burton C, Anderson N, Wilde K, Simpson CR. Factors associated with duration of new
10 antidepressant treatment: analysis of a large primary care database. *Br J Gen Pract*.
11 2012;62(595):e104-12.
12
13
- 14 19. Petty DR, House A, Knapp P, Raynor T, Zermansky A. Prevalence, duration and
15 indications for prescribing of antidepressants in primary care. *Age Ageing*.
16 2006;35(5):523-6.
17
18
- 19 20. Read J, Gibson KL, Cartwright C. Are older people prescribed antidepressants on the
20 basis of fewer symptoms of depression, and for longer periods of time? A survey of 1825
21 New Zealanders. *Australas J Ageing*. 2016;35(3):193-7.
22
23
- 24 21. Lu CY, Roughead E. New users of antidepressant medications: first episode duration and
25 predictors of discontinuation. *European journal of clinical pharmacology*. 2012;68(1):65-
26 71.
27
28
- 29 22. Lamberts H, Wood M. *International Classification of Primary Care*. Oxford: Oxford
30 University Press; 1987 1987.
31
32
- 33 23. Rashbash J, Charlon C, Browne WJ, Healy M, Cameron B. MLwiN Version 2.30.
34 Bristol2009.
35
36
- 37 24. Carey M, Jones K, Meadows G, Sanson-Fisher R, D'Este C, Inder K, et al. Accuracy of
38 general practitioner unassisted detection of depression. *Aust N Z J Psychiatry*.
39 2014;48(6):571-8.
40
41
- 42 25. Gotzsche PC. Antidepressants are addictive and increase the risk of relapse. *BMJ*.
43 2016;352:i574.
44
45
46
47
48
49
50
51
52
53


- 1
2
3 26. Greenberg G. *Manufacturing depression: the secret history of a modern disease*. London:
4 Bloomsbury; 2010.
- 5
6
7 27. Gotzsche PC, Young AH, Crace J. Does long term use of psychiatric drugs cause more
8 harm than good? *BMJ*. 2015;350:h2435.
- 9
10
11 28. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial
12 severity and antidepressant benefits: a meta-analysis of data submitted to the Food and
13 Drug Administration. *PLoS medicine*. 2008;5(2):e45.
- 14
15
16 29. Cuijpers P, van Straten A, van Oppen P, Andersson G. Are psychological and
17 pharmacologic interventions equally effective in the treatment of adult depressive
18 disorders? A meta-analysis of comparative studies. *The Journal of clinical psychiatry*.
19 2008;69(11):1675-85; quiz 839-41.
- 20
21
22 30. Andrews PW, Thomson JA, Jr., Amstadter A, Neale MC. Primum non nocere: an
23 evolutionary analysis of whether antidepressants do more harm than good. *Front*
24 *Psychol*. 2012;3:117.
- 25
26
27 31. Mark TL, Joish VN, Hay JW, Sheehan DV, Johnston SS, Cao Z. Antidepressant use in
28 geriatric populations: the burden of side effects and interactions and their impact on
29 adherence and costs. *Am J Geriatr Psychiatry*. 2011;19(3):211-21.
- 30
31
32 32. Johnson CF, Williams B, MacGillivray SA, Dougall NJ, Maxwell M. 'Doing the right
33 thing': factors influencing GP prescribing of antidepressants and prescribed doses. *BMC*
34 *Fam Pract*. 2017;18(1):72.
- 35
36
37 33. Bosman RC, Huijbregts KM, Verhaak PF, Ruhe HG, van Marwijk HW, van Balkom AJ,
38 et al. Long-term antidepressant use: a qualitative study on perspectives of patients and
39 GPs in primary care. *Br J Gen Pract*. 2016;66(651):e708-19.
- 40
41
42 34. Sinclair JE, Aucott LS, Lawton K, Reid IC, Cameron IM. The monitoring of longer term
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 prescriptions of antidepressants: observational study in a primary care setting. *Fam Pract.*
4
5 2014;31(4):419-26.
6

7
8 35. Burton C, Cameron I, Anderson N. Explaining the variation between practices in the
9
10 duration of new antidepressant treatment: a database cohort study in primary care. *Br J*
11
12 *Gen Pract.* 2015;65(631):e114-20.
13

14
15 36. Groot PC, Consensusgroep T. [Taperingstrips for paroxetine and venlafaxine]. *Tijdschr*
16
17 *Psychiatr.* 2013;55(10):789-94.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: proportion of AD-users in 2011, who used AD chronically in the subsequent years



Each column shows the proportions using antidepressants, SSRIs or TCAs based on those who received at least four prescriptions of that drug in 2011 (the start year; 100%). By 2015, only 42% of antidepressant users continued to use them through each year to 2015; for SSRI and TCA use, this rate was 38% and 35%, respectively.

254x190mm (96 x 96 DPI)

Table 1. Odds for receiving an SSRI prescription each year between 2011 and 2015

Variable	Coefficient	Standard Error	p-value	Odds ratio	95% Confidence Interval	
Sex (male = ref)						
Female	0.1699	0.0576	0.0032	1.19	1.06	1.33
Age (65+ = ref)						
19–44	-0.1077	0.0767	0.1600	0.90	0.77	1.04
45–64	0.2582	0.0700	0.0002	1.29	1.13	1.49
Disorder						
Anxiety (no anxiety = ref)	0.0333	0.0771	0.6656	1.03	0.89	1.20
Depression (ibidem)	-0.1207	0.0698	0.0838	0.89	0.77	1.02
Somatic disorder (ibidem)	0.1537	0.0849	0.0703	1.17	0.99	1.38
Practice variance	4.711	0.626				
ICC	0.59					
Constant	-3.6397	0.2066				

Table 2. Odds for receiving a TCA prescription during each year between 2011 and 2015

Variable	Coefficient	Standard Error	p-value	Odds ratio	95% Confidence Interval	
Sex (male = ref)						
Female	0.2030	0.0917	0.0268	1.23	1.02	1.47
Age (65+ = ref)						
19–44	-0.6821	0.1300	0.0000	0.51	0.39	0.65
45–64	0.0393	0.0915	0.6673	1.04	0.87	1.24
Disorder						
Anxiety (no anxiety = ref)	0.2098	0.1387	0.1303	1.23	0.94	1.62
Depression (ibidem)	0.3797	0.1137	0.0008	1.46	1.17	1.83
Somatic disorder (ibidem)	-0.0631	0.1098	0.5654	0.94	0.76	1.16
Practice variance	2.763	0.4156				
ICC	0.46					
Constant	-3.6022	0.1936				

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Action
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	In abstract
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	done
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	done
Objectives	3	State specific objectives, including any prespecified hypotheses	"we aimed to assess the extent of chronic antidepressant prescribing and to evaluate the determinants of that chronic prescribing."
Methods			
Study design	4	Present key elements of study design early in the paper	Design is presented in first paragraph of Method section
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Not applicable
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	Not applicable
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Done: we defined outcome measures and independent variables
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	done
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	Not applicable
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Done
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	done
		(b) Describe any methods used to examine subgroups and interactions	done
		(c) Explain how missing data were addressed	Not applicable

(d) If applicable, describe analytical methods taking account of sampling strategy

(e) Describe any sensitivity analyses

Results

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	Not applicable Not applicable Not applicable
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest	Done Not applicable
Outcome data	15*	Report numbers of outcome events or summary measures	Done
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Done Not applicable Not applicable
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	

Discussion

Key results	18	Summarise key results with reference to study objectives	Done
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Done
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Done
Generalisability	21	Discuss the generalisability (external validity) of the study results	Done

Other information

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Not applicable
---------	----	---	----------------

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

For peer review only

BMJ Open

What proportion of initially prescribed antidepressants is still being prescribed chronically after 5 year in general practice? A longitudinal cohort analysis.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024051.R1
Article Type:	Research
Date Submitted by the Author:	18-Sep-2018
Complete List of Authors:	Verhaak, Peter FM; Netherlands Institute of Health Services Research; Universitair Medisch Centrum Groningen, general practice de Beurs, Derek; Netherlands Institute of Health Services Research Spreeuwenberg, Peter; Netherlands Institute of Health Services Research
Primary Subject Heading:	General practice / Family practice
Secondary Subject Heading:	Epidemiology, General practice / Family practice, Mental health
Keywords:	PRIMARY CARE, Anxiety disorders < PSYCHIATRY, Depression & mood disorders < PSYCHIATRY

SCHOLARONE™
Manuscripts

1
2
3 **What proportion of initially prescribed antidepressants is still being prescribed**
4 **chronically after 5 year in general practice? A longitudinal cohort analysis.**
5
6
7

8
9 *Article category:* Epidemiology
10

11
12
13 Verhaak PFM¹, Beurs DP² de, Spreeuwenberg P²
14
15

16
17
18 ¹ Netherlands institute of health services research (NIVEL), Utrecht, the Netherlands
19

20 University of Groningen, University Medical Center Groningen, Department of General
21 Practice, Groningen, the Netherlands
22

23
24 ² Netherlands institute of health services research, Utrecht, the Netherlands
25
26
27
28
29
30

31 *Corresponding author:*
32

33 Prof. dr P. F. M. Verhaak
34

35 Netherlands institute of health services research (NIVEL)
36

37 P.O. Box 1568
38

39 3500 BN Utrecht
40

41 The Netherlands
42

43 p.verhaak@nivel.nl
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Abstract

Objectives. Antidepressant prescribing almost doubled in the Netherlands between 1996 and 2012, which could be accounted for by longer continuation after the first prescription. This might be problematic given a growing concern of large-scale antidepressant dependence. We aimed to assess the extent and determinants of chronic antidepressant prescribing among patient aged 18 years and older. We hypothesize a relatively large prevalence of chronic (> 2 years) prescription.

Design A longitudinal observational study based on routinely registered prescription data from general practice

Setting. 189 General practices in the Netherlands

Participants. 326,025 patients with valid prescription data for all five years of the study

Outcome measures. Primary outcome measure: the number of patients (N) receiving at least four antidepressant prescriptions in 2011, as well as during each of the four subsequent years. Secondary outcome measure: the above, but specified for Selective Serotonin Reuptake Inhibitors and for Tricyclic Antidepressants

Results. Antidepressants were prescribed to almost 7% of our 326,025 participants each year. They were prescribed for depression (38%), for anxiety (17%), other psychological disorders (20%) and non-psychological indications (25%). Antidepressants were prescribed in all five years to the 42% of the population who had at least four prescriptions dispensed in 2011. Chronic prescribing was higher among women than men, for those aged 45–64 years than for those aged >65 years and for those treated for depression or anxiety than for non-psychological indications (e.g., neuropathic pain). Chronic prescribing also varied markedly among general practices.

Conclusion. Chronic antidepressant use is common not only for depression but also for anxiety and non-psychological diagnoses. Once antidepressants have been prescribed, general

1
2
3 practitioners and other prescribers should be aware of the risks associated with long-term use
4
5 and should provide annual monitoring of the continued need for therapy.
6
7

8 9 **Strengths and limitations of the study**

- 11 • Strength: Large database, largely representative for Dutch population
- 12
- 13 • Strength: Routinely collected prescription data, reliable because needed for delivery
- 14
- 15 by pharmacist
- 16
- 17
- 18 • Limitation: Morbidity data, needed for prescription *indication*, are dependent on
- 19
- 20 coding by GP
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

INTRODUCTION

Antidepressants are recommended for the treatment of both major depression and anxiety disorders in most clinical guidelines. Based on evidence that they are more efficacious than placebo in adults with major depressive disorder(1), antidepressants were used by more than 12% of the adult US population in 2013, with the prevalence in women being approximately double that in men, and increasing with age(2). However, antidepressants are also prescribed off-label for disorders other than depression, most often in nursing homes and for older populations, with evidence supporting off-label use available in Dutch, UK, Swedish, Canadian and US populations (3-7). In the Netherlands, selective serotonin reuptake inhibitors (SSRIs) have typically been prescribed off-label for other psychological problems, while tricyclic antidepressants (TCAs) have tended to be preferred for pain disorders (3).

Dutch guidelines for the treatment of depression in general practice initially recommend watchful waiting and non-medical therapy, except for comparably rare presentations with suicidal ideation or psychosis. If symptoms persist, antidepressant medication can be considered if a depressive disorder is present, but not merely for the presence of depressive symptoms (8). According to the Dutch College of General Practitioners, psychopharmacological agents should not be used to treat anxiety symptoms, but they are considered to have efficacy for anxiety disorders (9). Despite this cautious approach, the prevalence of antidepressant prescribing almost doubled between 1996 and 2012 in the Netherlands (10).

In the 1990s, there was an increase in the prevalence and incidence of SSRI use, with more patients starting SSRIs and receiving antidepressant therapy for longer durations (11-16). An explanation for this increase in antidepressant prescribing might, therefore, be longer continuation after initial treatment. For example, Mars et al.(14) reported that the incidence of antidepressant prescriptions was stable between 1995 and 2011, but that the prevalence more

1
2
3 than doubled in the same period. In the Netherlands, Noordam et al. (10) showed the same
4 trends between 1996 and 2012. Given that equal numbers start therapy each year, but the total
5 number of users increases, the increase in prevalence might reflect longer continuation of
6 therapy.
7
8
9

10
11 Long-term antidepressant use has been reported in several studies that have used primary care
12 databases. In a recent Dutch study, antidepressants were used long-term (>15 months) by
13 30% and 44% in the periods 1995–2005 and 2005–2015, respectively(17). In a study of a
14 primary care database from Scotland, 40% of patients received SSRIs for longer than 180
15 days, and it was shown that practice variation accounted for most of the differences in
16 prescribing durations (18). In UK general practice, it has been reported that the mean
17 durations of antidepressant treatment were 4.8 years for depression, 7.4 years for anxiety and
18 5 years for pain (19). Read et al. also reported that 52% of a New Zealand sample continued
19 antidepressant treatment for three or more years, with this proportion increasing with age(20),
20 while Ambresin et al. reported that therapy was continued for more than 2 years in 47% of
21 antidepressant users. However, Sihvo (12) reported that only 14% of antidepressant users in
22 Finland continued therapy for more than two years. The results of an Australian study were
23 consistent with this latter finding, showing that 50% and 61% of new antidepressant users
24 had discontinued therapy within 6 and 12 months, respectively, and that only 20% had
25 continued therapy at three years. Receiving psychological or psychiatric care was associated
26 with longer antidepressant use, while the presence of either cancer or multiple morbidities
27 was associated with an increased likelihood of shorter treatment duration (21).
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 Little is known about the factors associated with long-term antidepressant use. Moreover,
50 although current Dutch guidelines recommend stopping treatment six months after remission
51 (9), they are not explicit about how to stop or about when long-term continuation is
52 appropriate. Regular monitoring and medication reviews are also recommended when
53
54
55
56
57
58
59
60

1
2
3 prescribing continues in the long term. Overall, the current real-world situation raises many
4 questions about the appropriateness of the current guidelines for clinical practice. Therefore,
5 we aimed to assess the extent of chronic antidepressant prescribing and to evaluate the
6 determinants of that chronic prescribing. Our main research questions were what proportion
7 of patients were prescribed antidepressants continuously during a five-year period and what
8 predicted long-term prescribing? We also wanted to answer four specific sub-questions: (1)
9 What proportions of patients continue therapy for more than two, three and four years? (2)
10 Are there differences in long-term prescribing by sex and age? (3) Are there differences in
11 long-term prescribing by the indication for antidepressant prescribing? and (4) Are there
12 differences in long-term prescribing between SSRIs and TCAs?
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 **METHOD**

28 **Study design and participants**

29
30 This was a cross-sectional observational study based on the data obtained in the NIVEL
31 Primary Care Database (NPCD). Participants were all patients aged 18 years and older,
32 registered in Dutch general practices participating in the NPCD.
33
34
35
36
37
38
39

40 **NIVEL Database**

41
42 Data were obtained from the NPCD. This database contains routinely collected data on
43 symptoms, diagnoses, medications and laboratory results related to the consultations for
44 patients from 367–519 general practices (the number of participating practices each year
45 varied) in the Netherlands. All non-institutionalised inhabitants of the Netherlands are
46 registered at a general practice, and the general practices and patient populations in the
47 NPCD have proven representativeness for wider Dutch society, although group practices are
48 somewhat overrepresented. For this study, we used data for adult patients aged 18 years and
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 older, covering the period 2011–2015.

4 5 ***Patient and Public involvement***

6
7
8 The data collection was approved by our institutional review board, who waived the need to
9
10 obtain specific consent. The study was conducted in accordance with the requirements of the
11
12 Helsinki Declaration. Patients in participating practices are informed about participation of
13
14 the practice in NPCD with an opportunity for opting out.
15

16 17 **Data**

18 19 ***Prescriptions***

20
21 Each medication prescription, including repeat prescriptions, were recorded by date and code
22
23 based on the Anatomical Therapeutic Chemical Classification System (i.e., ATC codes). The
24
25 following codes for antidepressants were included: N06AA (TCA), N06AB (SSRI), N06AF
26
27 (non-selective monoamine oxidase inhibitors [MAOI]), N06AG (type A MAOI) and N06AX
28
29 (other antidepressants).
30
31

32 33 ***Diagnosis***

34
35 Symptoms and diagnoses related to a given prescription were classified according to the
36
37 International Classification of Primary Care (22), using the P.xxxx codes for psychological
38
39 symptoms and disorders. Codes P03 (depressive symptom) and P76 (depressive disorder)
40
41 were taken to mean ‘depression’, while codes P01 (feeling nervous) and P74 (anxiety
42
43 disorder) were taken to mean ‘anxiety’. Codes not in Chapter P were recorded as somatic
44
45 symptoms and diagnoses.
46
47

48 49 ***Prevalence of antidepressant prescription***

50
51 For each year, we calculated the number of patients (N) prescribed an antidepressant, SSRI or
52
53 TCA and whether the prescription was linked to a record of depression, anxiety or other
54
55 disorder (non-psychological/somatic). We recorded the number of patients with a prescription
56
57
58
59

per 1000 patient-years, linked to age and gender, within a certain year. These data allow for extrapolation to the Dutch population based on a yearly weighted population at risk in the NPCD, which varied annually from 1,087,395 to 1,641,806 patient-years.

Long-term use

To calculate the numbers of patients using prescriptions for several years, the data for different years were merged to give the number of patients with a recorded antidepressant prescription and diagnosis of depression in each of the study years (i.e., 2011, 2012, 2013, 2014 and 2015). Merging data for the five subsequent years resulted in a loss of cases, because the NIVEL database did not include all practices or patients in some years.

Statistical Analysis

We use multilevel logistic regression with patients clustered by general practice. The models were then analysed in MLwiN 2.30 (23), using with the options 'PQL' and 'second order' ('first order' was used if the model failed to converge), and 'constrained level one variance'.

Outcome measures

The main outcome measure was the number of patients (N) receiving at least four antidepressant prescriptions in 2011, as well as during each of the four subsequent years. We assumed that receiving four or more prescriptions in one year was consistent with chronic use, based on the common Dutch practice to prescribe antidepressants on repeat prescriptions for three-month periods.

Independent variables

At Level 1, we controlled for variation at the practice level. At Level 2, the patient level, we considered age in 2011, sex and diagnosis associated with the prescription (i.e., depression, anxiety or somatic problem)

RESULTS

The results about long-term antidepressants use are based on data for 326,025 patients (older than 18 years) from 189 practices with valid prescription data for all five years of the study.

In 2011, antidepressants were prescribed to $\pm 71/1000$ registered patients aged ≥ 18 years.

About two-thirds of the prescriptions were for women and about one-third were for men.

30% of antidepressants were prescribed to, those aged 18–44 years, 45% to 45–64 years old and 25% to those above 65 years. The distribution of the population at risk in 2011 was 43:37:20

Of the antidepressants prescribed, SSRIs and TCAs accounted for 52% and 28%, respectively. Overall, 38% were prescribed for depression, 17% for anxiety, 20% for other psychological diagnoses and 25% for somatic indications. SSRIs were more frequently prescribed for depression (47%) and anxiety (23%), while TCAs tended to be prescribed frequently for somatic disorders (44%) or other psychological disorders (21%). The main somatic indications for TCAs were generalised pain (1.7%), lumbago (2.5%), low backpain with radiation (2.5%), headache (2.7%), tension headache (2%), neuropathy (4.8%), sleeping problems (4.1%) and type 2 diabetes mellitus (1.5%).

The data for the proportions of patients who continued to be prescribed antidepressants in each year after 2011 are summarised in Figure 1 and Table 1.

Here figure 1

Of those who received at least four prescriptions in 2011, we found that 65% were still receiving at least four prescriptions per year at two years and that 58% were still receiving them at three years. However, only 42% of patients received at least four prescriptions of antidepressants through each year from 2011 to 2015; by SSRI and TCA use, this was 38% and 35%, respectively (Figure 1).

When we lower the threshold for chronic prescribing to at least one prescription a year, 65% of patients receiving an AD prescription in 2011 kept receiving yearly at least one prescription each year to 2015.

The odds for receiving antidepressants over five consecutive years based on patients' characteristics are shown in Table 1.

Table 1. Odds for Receiving an Antidepressant for Each Year between 2011 and 2015 after Receiving the First Prescription in 2011

Variable	Coefficient	SE	p-value	OR	95% CI	
Sex (ref = male)						
Female	0.1400	0.0409	0.0006	1.15	1.06	1.25
Age (ref = 65+ years)						
19–44	-0.1161	0.0541	0.0320	0.89	0.80	0.99
45–64	0.2320	0.0476	0.0000	1.26	1.15	1.38
Disorder						
Anxiety (ref = no anxiety)	0.3196	0.0558	0.0000	1.38	1.23	1.54
Depression (ref = no depression)	0.3224	0.0488	0.0000	1.38	1.25	1.52
Somatic disorder (ref = no somatic disorder)	0.0153	0.0565	0.7864	1.02	0.91	1.13
Practice variance	6.763	0.8653				
ICC	0.67					
Constant	-4.2012	0.2276				

Abbreviations: CI, confidence interval; ICC, intraclass correlation coefficient; OR, odds ratio; SE, standard error

Specifically, the odds were higher for women than for men, for patients aged 45–65 years and for a diagnosis of anxiety or depression. However, there was substantial practice variation, meaning that the proportions were even larger in some practices but much smaller in others.

Tables 1 and 2 in the appendix show similar patterns for SSRIs and TCAs analysed separately, though with some exceptions. A diagnosis of anxiety, for example, did not affect

1
2
3 long-term SSRI prescribing. Also, sex and older age affected long-term TCA prescribing, but
4
5 indication did not.
6
7
8
9

10 **DISCUSSION**

11
12 Antidepressants were prescribed to almost 7% of the general practice population, aged 18
13
14 years and older, in this study. The main indication was for depression (38%), but anxiety
15
16 (17%), other psychological disorders (20%) and non-psychological indications, mostly pain
17
18 related (25%), were frequent. Interestingly, nearly half of the population (42%) received
19
20 antidepressants throughout all five years of the study. The odds of long-term use were higher
21
22 for women than for men, for those aged 45–64 years than for those aged ≥ 65 years and for
23
24 those with psychological indications than for those with non-psychological indications.
25
26 However, long-term prescribing habits varied markedly among practices.
27
28

29
30 Consistent with our results, Huijbregts et al. (17) reported that about 44% of antidepressant
31
32 use was long term (defined as >15 months) based on one region in the Netherlands. In our
33
34 larger nationwide population, with a much stricter definition of long-term use as five years of
35
36 continuous receipt of four antidepressant prescriptions a year, 42% used antidepressants
37
38 chronically. We also found the same risk factors for long-term use, with female sex, older
39
40 age, and having a diagnosis of anxiety or depression being most important. However, in
41
42 contrast with their data, we found that the group aged 45–64 years was at higher risk than the
43
44 group aged ≥ 65 years.
45
46

47
48 Antidepressant medication use is a prominent topic of discussion in society. Opponents of
49
50 their widespread use, such as Götzsche(24) and Greenberg(25), point to the lack of efficacy
51
52 and the possible harms of long-term use. Risk of falls and fractures, upper gastro-intestinal
53
54 bleed and epilepsy/seizures is increased among adult (20-64 year)AD users(26, 27). A higher
55
56
57
58
59
60

1
2
3 risk for falls, attempted suicides, stroke, fracture and epilepsy is reported for older people,
4 using AD(28). By contrast, proponents, such as Young and Crace(29), consider psychiatric
5 drugs to be as beneficial as other medical treatments and argue that concerns about long-term
6 use are overinflated. So, just how harmful is antidepressant use in the long term? We know
7 that antidepressant use is now on a large scale, partly for depression and anxiety, but also for
8 other psychological and non-psychological indications. This is important to understand
9 because antidepressants have only demonstrated slight effectiveness for the treatment of
10 depression and anxiety (30), and have unknown efficacy for those other disorders. Although
11 some patients will benefit from long-term use (31), at best, such use may be unhelpful to
12 many patients. Indeed, there is no conclusive evidence about the safety of antidepressants
13 over years, and Andrews et al. even claim that such use will generally do more harm than
14 good by disrupting key adaptive processes regulated by serotonin(32). Harm may also be
15 expected among older antidepressant users who are at risk of polypharmacy; antidepressant
16 use, for example, has an important negative impact on the Drug Burden Index, an indicator of
17 the cholinergic and sedative stress imposed by medication(33).

18
19
20 At first glance, general practitioners (GPs) might view antidepressant treatment as a good
21 initial therapy that is in the patient's interest. Despite the potential risks, and perhaps because
22 of the lack of clear evidence of harm, or reports of continuation problems, the option of long-
23 term use also remains acceptable (34). This is compounded by the fact that, when patients
24 have benefitted from relief of depressive symptoms, they often become reluctant to stop
25 therapy for fear of becoming depressed again(35). Therefore, large groups of patients with
26 single episodes of low severity depression, who probably received effective antidepressant
27 therapy in the beginning, progress to long-term use with less clearly defined benefits.

28
29
30 A way to prevent unnecessary long-term antidepressant use might be to institute annual
31 medication reviews. This issue is especially pertinent given that proactive medication reviews

1
2
3 have been reported to become increasingly sparse the longer antidepressants have been
4 prescribed, especially when not for an overt mental health reason(36).
5
6

7
8 The large practice variation that we found suggests long term AD prescribing to be a practice
9 policy, as has been reported in the case of antibiotics prescribing(37), where patient
10 characteristics could not explain the variation at practice level as well(38). Medication
11 reviews may reflect such a policy, possibly by routine consultations between GP and
12 pharmacist. As proven in other studies, medication reviews may be routine in some practices,
13 leading to reduced long-term antidepressant use, but may non-existent in other practices, with
14 opposing results (39). New initiatives, such as the introduction of tapering strips(40) or the
15 continuous monitoring of patients who discontinue antidepressants, could offer new insights
16 and help develop recommendations for GPs to help patients stop treatment when it is no
17 longer needed. Developing a consensus on how to discontinue antidepressants in general
18 practice could reduce practice variation and decrease the proportions of patients who continue
19 to take antidepressants beyond the required period for acute treatment and stabilization.
20
21
22
23
24
25
26
27
28
29
30
31
32

33 34 **Limitations**

35
36 Although prescription data were available of 1–2 million patients, substantial numbers were
37 lost by merging prescription and morbidity data (providing us with the indication) and by
38 merging the data over several years (e.g., some practices were not part of the NPCD for the
39 full period and some patients were not registered for the full period). Therefore, the final
40 analyses were conducted on 326,025 cases from 189 practices. This final sample included
41 more patients aged >45 years and fewer men compared with the original database, so may
42 have not been truly representative of the Dutch population. Our definition of chronic
43 prescribing (at least four prescriptions in all years) is arbitrary. However, when we increase
44 the threshold to e.g. five prescriptions a year, chronic users having a repeat prescription each
45 three months would not be included. When we decrease the threshold to one prescription in
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

each of five years, the number of “chronic users” increases to 65%. Morbidity data were also highly dependent on the coding registered by the GP. It is well known that GP variations in diagnosis are large and that sensitivity can be suboptimal(41). However, the antidepressant prescribing data were not dependent on the morbidity coding, which is a major strength.

Conclusions

Chronic antidepressant use was common in this cohort, with 42% of patients prescribed antidepressants in 2011 continuing to use them at five years. Although the initial prescribing of antidepressants might have become stable, patients continue to take their prescriptions for many years, though with considerable variation in this trend between practices. It was noteworthy that depression was not the main indication for antidepressant prescription, with a quarter of prescriptions being for non-psychological indications and a fifth being for anxiety. Therefore, we conclude that the high levels of antidepressant use can only partly be attributed to depression, with the main issue appearing to be an increase in chronic usage after initial prescribing. GPs and other prescribers should be aware of the risks of long-term antidepressant use and ensure annual monitoring to reduce unnecessary prescribing.

Figure 1: number of AD-users in 2011, who used AD chronically (≥ 4 prescription/year) in the subsequent years.

Legend: ■: Total Antidepressants

■: SSRI

■: TCA

Acknowledgements

We thank Dr Robert Sykes (www.doctored.org.uk) for providing editorial services.

Author contributions

Peter Verhaak conceived the concept, analysed the data and wrote the paper. Derek de Beurs discussed the concept and commented on all drafts. Peter Spreeuwenberg performed the multilevel analysis and commented on all drafts.

Conflicts of interest

None

Funding

There is no funding to be reported. All authors are appointed by the Netherlands Institute of Health Services Research and had access to NIVEL Primary Care Database.

Transparency declaration

The lead author (PV) affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Ethical issues

The data collection was approved by our institutional review board, who waived the need to obtain specific consent. The study was conducted in accordance with the requirements of the Helsinki Declaration. Patients in participating practices were informed about the practice's participation in NPCD and were free to opt out.

Data sharing statement

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

We've got access to the anonymous database under condition that data will be used only for the answering of the current research questions.

For peer review only

References


1. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *The Lancet*. 2018;dx.doi.org/10.1016/50140-6736(17)32802-7.
2. Moore TJ, Mattison DR. Adult Utilization of Psychiatric Drugs and Differences by Sex, Age, and Race. *JAMA Intern Med*. 2017;177(2):274-5.
3. Aarts N, Noordam R, Hofman A, Tiemeier H, Stricker BH, Visser LE. Self-reported indications for antidepressant use in a population-based cohort of middle-aged and elderly. *Int J Clin Pharm*. 2016;38(5):1311-7.
4. Hanlon JT, Wang X, Castle NG, Stone RA, Handler SM, Semla TP, et al. Potential underuse, overuse, and inappropriate use of antidepressants in older veteran nursing home residents. *Journal of the American Geriatrics Society*. 2011;59(8):1412-20.
5. Harris T, Carey IM, Shah SM, DeWilde S, Cook DG. Antidepressant prescribing in older primary care patients in community and care home settings in England and Wales. *J Am Med Dir Assoc*. 2012;13(1):41-7.
6. Midlov P, Andersson M, Ostgren CJ, Molstad S. Depression and use of antidepressants in Swedish nursing homes: a 12-month follow-up study. *International psychogeriatrics / IPA*. 2014;26(4):669-75.
7. Wong J, Motulsky A, Abrahamowicz M, Egale T, Buckeridge DL, Tamblyn R. Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system. *BMJ*. 2017;356:j603.
8. Weel-Baumgarten EMv, Gelderen MGv, Grundmeijer HGLM, Licht-Strunk E, Marwijk HWJv, Rijswijk HCAMv, et al. NHG-Standaard Depressie (tweede herziening). *Huisarts & Wetenschap*. 2012;55(6):252-9.
9. Hassink-Franke L, Terluin B, Heest Fv, Hekman J, Marwijk Hv, Avendonk Mv. NHG-Standaard Angst (tweede herziening). Utrecht: Nederlands Huisarts Genootschap, 2012.
10. Noordam R, Aarts N, Verhamme KM, Sturkenboom MC, Stricker BH, Visser LE. Prescription and indication trends of antidepressant drugs in the Netherlands between 1996 and 2012: a dynamic population-based study. *European journal of clinical pharmacology*. 2015;71(3):369-75.
11. Meijer WE, Heerdink ER, Leufkens HG, Herings RM, Egberts AC, Nolen WA. Incidence and determinants of long-term use of antidepressants. *European journal of clinical pharmacology*. 2004;60(1):57-61.
12. Sihvo S, Wahlbeck K, McCallum A, Sevon T, Arffman M, Haukka J, et al. Increase in the duration of antidepressant treatment from 1994 to 2003: a nationwide population-based study from Finland. *Pharmacoepidemiol Drug Saf*. 2010;19(11):1186-93.
13. Mojtabai R, Olfson M. National trends in long-term use of antidepressant medications: results from the U.S. National Health and Nutrition Examination Survey. *The Journal of clinical psychiatry*. 2014;75(2):169-77.
14. Mars B, Heron J, Kessler D, Davies NM, Martin RM, Thomas KH, et al. Influences on antidepressant prescribing trends in the UK: 1995-2011. *Soc Psychiatry Psychiatr Epidemiol*. 2017;52(2):193-200.
15. Moore M, Yuen HM, Dunn N, Mullee MA, Maskell J, Kendrick T. Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database. *BMJ*. 2009;339:b3999.
16. Lockhart P, Guthrie B. Trends in primary care antidepressant prescribing 1995-2007: a longitudinal population database analysis. *Br J Gen Pract*. 2011;61(590):e565-72.
17. Huijbregts KM, Hoogendoorn A, Slottje P, van Balkom A, Batelaan NM. Long-Term and Short-Term Antidepressant Use in General Practice: Data from a Large Cohort in the Netherlands. *Psychother Psychosom*. 2017;86(6):362-9.

18. Burton C, Anderson N, Wilde K, Simpson CR. Factors associated with duration of new antidepressant treatment: analysis of a large primary care database. *Br J Gen Pract*. 2012;62(595):e104-12.
19. Petty DR, House A, Knapp P, Raynor T, Zermansky A. Prevalence, duration and indications for prescribing of antidepressants in primary care. *Age Ageing*. 2006;35(5):523-6.
20. Read J, Gibson KL, Cartwright C. Are older people prescribed antidepressants on the basis of fewer symptoms of depression, and for longer periods of time? A survey of 1825 New Zealanders. *Australas J Ageing*. 2016;35(3):193-7.
21. Lu CY, Roughead E. New users of antidepressant medications: first episode duration and predictors of discontinuation. *European journal of clinical pharmacology*. 2012;68(1):65-71.
22. Lamberts H, Wood M. *International Classification of Primary Care*. Oxford: Oxford University Press; 1987 1987.
23. Rashbash J, Charlton C, Browne WJ, Healy M, Cameron B. MLwiN Version 2.30. Bristol 2009.
24. Gotzsche PC. Antidepressants are addictive and increase the risk of relapse. *BMJ*. 2016;352:i574.
25. Greenberg G. *Manufacturing depression: the secret history of a modern disease*. London: Bloomsbury; 2010.
26. Coupland C, Hill T, Morriss R, Moore M, Arthur A, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in people aged 20-64 years: cohort study using a primary care database. *BMC Med*. 2018;16(1):36.
27. Hill T, Coupland C, Morriss R, Arthur A, Moore M, Hippisley-Cox J. Antidepressant use and risk of epilepsy and seizures in people aged 20 to 64 years: cohort study using a primary care database. *BMC Psychiatry*. 2015;15:315.
28. Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. *BMJ*. 2011;343:d4551.
29. Gotzsche PC, Young AH, Crace J. Does long term use of psychiatric drugs cause more harm than good? *BMJ*. 2015;350:h2435.
30. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. *PLoS medicine*. 2008;5(2):e45.
31. Cuijpers P, van Straten A, van Oppen P, Andersson G. Are psychological and pharmacologic interventions equally effective in the treatment of adult depressive disorders? A meta-analysis of comparative studies. *The Journal of clinical psychiatry*. 2008;69(11):1675-85; quiz 839-41.
32. Andrews PW, Thomson JA, Jr., Amstadter A, Neale MC. Primum non nocere: an evolutionary analysis of whether antidepressants do more harm than good. *Front Psychol*. 2012;3:117.
33. Mark TL, Joish VN, Hay JW, Sheehan DV, Johnston SS, Cao Z. Antidepressant use in geriatric populations: the burden of side effects and interactions and their impact on adherence and costs. *Am J Geriatr Psychiatry*. 2011;19(3):211-21.
34. Johnson CF, Williams B, MacGillivray SA, Dougall NJ, Maxwell M. 'Doing the right thing': factors influencing GP prescribing of antidepressants and prescribed doses. *BMC Fam Pract*. 2017;18(1):72.
35. Bosman RC, Huijbregts KM, Verhaak PF, Ruhe HG, van Marwijk HW, van Balkom AJ, et al. Long-term antidepressant use: a qualitative study on perspectives of patients and GPs in primary care. *Br J Gen Pract*. 2016;66(651):e708-19.
36. Sinclair JE, Aucott LS, Lawton K, Reid IC, Cameron IM. The monitoring of longer term prescriptions of antidepressants: observational study in a primary care setting. *Fam Pract*. 2014;31(4):419-26.
37. Kim JK, Chua ME, Ming JM, Braga LH, Smith GHH, Driver C, et al. Practice variation on use of antibiotics: An international survey among pediatric urologists. *J Pediatr Urol*. 2018.

- 1
2
3 38. Manne M, Deshpande A, Hu B, Patel A, Taksler GB, Misra-Hebert AD, et al. Provider Variation
4 in Antibiotic Prescribing and Outcomes of Respiratory Tract Infections. *South Med J*.
5 2018;111(4):235-42.
6 39. Burton C, Cameron I, Anderson N. Explaining the variation between practices in the duration
7 of new antidepressant treatment: a database cohort study in primary care. *Br J Gen Pract*.
8 2015;65(631):e114-20.
9 40. Groot PC, Consensusgroup T. [Taperingstrips for paroxetine and venlafaxine]. *Tijdschr*
10 *Psychiatr*. 2013;55(10):789-94.
11 41. Carey M, Jones K, Meadows G, Sanson-Fisher R, D'Este C, Inder K, et al. Accuracy of general
12 practitioner unassisted detection of depression. *Aust N Z J Psychiatry*. 2014;48(6):571-8.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: number of AD-users in 2011, who used AD chronically (≥ 4 prescription/year) in the subsequent years



254x190mm (300 x 300 DPI)

Table 1. Odds for receiving an SSRI prescription each year between 2011 and 2015

Variable	Coefficient	Standard Error	p-value	Odds ratio	95% Confidence Interval	
Sex (male = ref)						
Female	0.1699	0.0576	0.0032	1.19	1.06	1.33
Age (65+ = ref)						
19–44	-0.1077	0.0767	0.1600	0.90	0.77	1.04
45–64	0.2582	0.0700	0.0002	1.29	1.13	1.49
Disorder						
Anxiety (no anxiety = ref)	0.0333	0.0771	0.6656	1.03	0.89	1.20
Depression (no depression = ref)	-0.1207	0.0698	0.0838	0.89	0.77	1.02
Somatic disorder (no somatic disorder = ref)	0.1537	0.0849	0.0703	1.17	0.99	1.38
Practice variance	4.711	0.626				
ICC	0.59					
Constant	-3.6397	0.2066				

Table 2. Odds for receiving a TCA prescription during each year between 2011 and 2015

Variable	Coefficient	Standard Error	p-value	Odds ratio	95% Confidence Interval	
Sex (male = ref)						
Female	0.2030	0.0917	0.0268	1.23	1.02	1.47
Age (65+ = ref)						
19–44	-0.6821	0.1300	0.0000	0.51	0.39	0.65
45–64	0.0393	0.0915	0.6673	1.04	0.87	1.24
Disorder						
Anxiety (no anxiety = ref)	0.2098	0.1387	0.1303	1.23	0.94	1.62
Depression (no depression = ref)	0.3797	0.1137	0.0008	1.46	1.17	1.83
Somatic disorder (no somatic disorder = ref)	-0.0631	0.1098	0.5654	0.94	0.76	1.16
Practice variance						
	2.763	0.4156				
ICC						
	0.46					
Constant						
	-3.6022	0.1936				

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Action
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	In abstract
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	done
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	done
Objectives	3	State specific objectives, including any prespecified hypotheses	“we aimed to assess the extent of chronic antidepressant prescribing and to evaluate the determinants of that chronic prescribing.”
Methods			
Study design	4	Present key elements of study design early in the paper	Design is presented in first paragraph of Method section
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Not applicable
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	Not applicable
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Done: we defined outcome measures and independent variables
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	done
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	Not applicable
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Done
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	done
		(b) Describe any methods used to examine subgroups and interactions	done
		(c) Explain how missing data were addressed	Not applicable

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

(d) If applicable, describe analytical methods taking account of sampling strategy

(e) Describe any sensitivity analyses

Results

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	Not applicable Not applicable Not applicable
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest	Done Not applicable
Outcome data	15*	Report numbers of outcome events or summary measures	Done
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Done Not applicable Not applicable
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	

Discussion

Key results	18	Summarise key results with reference to study objectives	Done
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Done
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Done
Generalisability	21	Discuss the generalisability (external validity) of the study results	Done

Other information

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Not applicable
---------	----	---	----------------

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

What proportion of initially prescribed antidepressants is still being prescribed chronically after 5 years in general practice? A longitudinal cohort analysis.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024051.R2
Article Type:	Research
Date Submitted by the Author:	05-Nov-2018
Complete List of Authors:	Verhaak, Peter FM; Netherlands Institute of Health Services Research; Universitair Medisch Centrum Groningen, general practice de Beurs, Derek; Netherlands Institute of Health Services Research Spreeuwenberg, Peter; Netherlands Institute of Health Services Research
Primary Subject Heading:	General practice / Family practice
Secondary Subject Heading:	Epidemiology, General practice / Family practice, Mental health
Keywords:	PRIMARY CARE, Anxiety disorders < PSYCHIATRY, Depression & mood disorders < PSYCHIATRY

SCHOLARONE™
Manuscripts

1
2
3 **What proportion of initially prescribed antidepressants is still being prescribed**
4 **chronically after 5 years in general practice? A longitudinal cohort analysis.**
5
6
7
8
9

10 *Article category:* Epidemiology
11
12
13

14 Verhaak PFM¹, Beurs D² de, Spreeuwenberg P²
15
16
17
18

19 ¹ Netherlands institute of health services research (NIVEL), Utrecht, the Netherlands
20

21 University of Groningen, University Medical Center Groningen, Department of General
22 Practice, Groningen, the Netherlands
23
24

25 ² Netherlands institute of health services research, Utrecht, the Netherlands
26
27
28
29
30
31
32

33 *Corresponding author:*
34

35 Prof. dr P. F. M. Verhaak
36

37 Netherlands institute of health services research (NIVEL)
38

39 P.O. Box 1568
40

41 3500 BN Utrecht
42

43 The Netherlands
44

45 p.verhaak@nivel.nl
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Abstract

Objectives. Antidepressant prescribing almost doubled in the Netherlands between 1996 and 2012, which could be accounted for by longer continuation after the first prescription. This might be problematic given a growing concern of large-scale antidepressant dependence. We aimed to assess the extent and determinants of chronic antidepressant prescribing among patient aged 18 years and older. We hypothesize a relatively large prevalence of chronic (> 2 years) prescription.

Design A longitudinal observational study based on routinely registered prescription data from general practice

Setting. 189 General practices in the Netherlands

Participants. 326,025 patients with valid prescription data for all five years of the study

Outcome measures. Primary outcome measure: the number of patients (N) receiving at least four antidepressant prescriptions in 2011, as well as during each of the four subsequent years. Secondary outcome measure: the above, but specified for Selective Serotonin Reuptake Inhibitors and for Tricyclic Antidepressants

Results. Antidepressants were prescribed to almost 7% of our 326,025 participants each year. They were prescribed for depression (38%), for anxiety (17%), other psychological disorders (20%) and non-psychological indications (25%). Antidepressants were prescribed in all five years to the 42% of the population who had at least four prescriptions dispensed in 2011. Chronic prescribing was higher among women than men, for those aged 45–64 years than for those aged >65 years and for those treated for depression or anxiety than for non-psychological indications (e.g., neuropathic pain). Chronic prescribing also varied markedly among general practices.

Conclusion. Chronic antidepressant use is common not only for depression but also for anxiety and non-psychological diagnoses. Once antidepressants have been prescribed, general

1
2
3 practitioners and other prescribers should be aware of the risks associated with long-term use
4
5 and should provide annual monitoring of the continued need for therapy.
6
7
8
9

10 **Strengths and limitations of the study**

- 12 • Strength: Large database, largely representative for Dutch population
 - 14 • Strength: Routinely collected prescription data, reliable because needed for delivery
16 by pharmacist
 - 18 • Limitation: Morbidity data, needed for prescription *indication*, are dependent on
20 coding by GP
- 21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Antidepressants are recommended for the treatment of both major depression and anxiety disorders in most clinical guidelines. Based on evidence that they are more efficacious than placebo in adults with major depressive disorder(1), antidepressants were used by more than 12% of the adult US population in 2013, with the prevalence in women being approximately double that in men, and increasing with age(2). However, antidepressants are also prescribed off-label for disorders other than depression, most often in nursing homes and for older populations, with evidence supporting off-label use available in Dutch, UK, Swedish, Canadian and US populations (3-7). In the Netherlands, selective serotonin reuptake inhibitors (SSRIs) have typically been prescribed off-label for other psychological problems, while tricyclic antidepressants (TCAs) have tended to be preferred for pain disorders (3).

Dutch guidelines for the treatment of depression in general practice initially recommend watchful waiting and non-medical therapy, except for comparably rare presentations with suicidal ideation or psychosis. If symptoms persist, antidepressant medication can be considered if a depressive disorder is present, but not merely for the presence of depressive symptoms (8). According to the Dutch College of General Practitioners, psychopharmacological agents should not be used to treat anxiety symptoms, but they are considered to have efficacy for anxiety disorders (9). Despite this cautious approach, the prevalence of antidepressant prescribing almost doubled between 1996 and 2012 in the Netherlands (10).

In the 1990s, there was an increase in the prevalence and incidence of SSRI use, with more patients starting SSRIs and receiving antidepressant therapy for longer durations (11-16). An explanation for this increase in antidepressant prescribing might, therefore, be longer continuation after initial treatment. For example, Mars et al.(14) reported that the incidence of antidepressant prescriptions was stable between 1995 and 2011, but that the prevalence more

1
2
3 than doubled in the same period. In the Netherlands, Noordam et al. (10) showed the same
4 trends between 1996 and 2012. Given that equal numbers start therapy each year, but the total
5 number of users increases, the increase in prevalence might reflect longer continuation of
6 therapy.
7
8
9
10
11

12 Long-term antidepressant use has been reported in several studies that have used primary care
13 databases. In a recent Dutch study, antidepressants were used long-term (>15 months) by
14 30% and 44% in the periods 1995–2005 and 2005–2015, respectively(17). In a study of a
15 primary care database from Scotland, 40% of patients received SSRIs for longer than 180
16 days, and it was shown that practice variation accounted for most of the differences in
17 prescribing durations (18). In UK general practice, it has been reported that the mean
18 durations of antidepressant treatment were 4.8 years for depression, 7.4 years for anxiety and
19 5 years for pain (19). Read et al. also reported that 52% of a New Zealand sample continued
20 antidepressant treatment for three or more years, with this proportion increasing with age(20),
21 while Ambresin et al. reported that therapy was continued for more than 2 years in 47% of
22 antidepressant users. However, Sihvo (12) reported that only 14% of antidepressant users in
23 Finland continued therapy for more than two years. The results of an Australian study were
24 consistent with this latter finding, showing that 50% and 61% of new antidepressant users
25 had discontinued therapy within 6 and 12 months, respectively, and that only 20% had
26 continued therapy at three years. Receiving psychological or psychiatric care was associated
27 with longer antidepressant use, while the presence of either cancer or multiple morbidities
28 was associated with an increased likelihood of shorter treatment duration (21).
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 Little is known about the factors associated with long-term antidepressant use. Moreover,
52 although current Dutch guidelines recommend stopping treatment six months after remission
53 (9), they are not explicit about how to stop or about when long-term continuation is
54 appropriate. Regular monitoring and medication reviews are also recommended when
55
56
57
58
59
60

1
2
3 prescribing continues in the long term. Overall, the current real-world situation raises many
4
5 questions about the appropriateness of the current guidelines for clinical practice. Therefore,
6
7 we aimed to assess the extent of chronic antidepressant prescribing and to evaluate the
8
9 determinants of that chronic prescribing. Our main research questions were what proportion
10
11 of patients were prescribed antidepressants continuously during a five-year period and what
12
13 predicted long-term prescribing? We also wanted to answer four specific sub-questions: (1)
14
15 What proportions of patients continue therapy for more than two, three and four years? (2)
16
17 Are there differences in long-term prescribing by sex and age? (3) Are there differences in
18
19 long-term prescribing by the indication for antidepressant prescribing? and (4) Are there
20
21 differences in long-term prescribing between SSRIs and TCAs?
22
23
24
25
26
27
28

29 **METHOD**

30 **Study design and participants**

31
32 This was a cross-sectional observational study based on the data obtained in the NIVEL
33
34 Primary Care Database (NPCD). Participants were all patients aged 18 years and older,
35
36 registered in Dutch general practices participating in the NPCD.
37
38
39
40
41

42 **NIVEL Database**

43
44 Data were obtained from the NPCD. This database contains routinely collected data on
45
46 symptoms, diagnoses, medications and laboratory results related to the consultations for
47
48 patients from 367–519 general practices (the number of participating practices each year
49
50 varied) in the Netherlands. All non-institutionalised inhabitants of the Netherlands are
51
52 registered at a general practice, and the general practices and patient populations in the
53
54 NPCD have proven representativeness for wider Dutch society, although group practices are
55
56 somewhat overrepresented. For this study, we used data for adult patients aged 18 years and
57
58
59
60

1
2
3 older, covering the period 2011–2015.
4
5

6 ***Patient and Public involvement***

7
8 Patients and Public were not involved in design or conduct of the study
9
10

11 **Data**

12 ***Prescriptions***

13
14 Each medication prescription, including repeat prescriptions, were recorded by date and code
15 based on the Anatomical Therapeutic Chemical Classification System (i.e., ATC codes). The
16 following codes for antidepressants were included: N06AA (TCA), N06AB (SSRI), N06AF
17 (non-selective monoamine oxidase inhibitors [MAOI]), N06AG (type A MAOI) and N06AX
18 (other antidepressants).
19
20
21
22
23
24
25
26
27

28 ***Diagnosis***

29 Symptoms and diagnoses related to a given prescription were classified according to the
30 International Classification of Primary Care (22), using the P.xxxx codes for psychological
31 symptoms and disorders. Codes P03 (depressive symptom) and P76 (depressive disorder)
32 were taken to mean ‘depression’, while codes P01 (feeling nervous) and P74 (anxiety
33 disorder) were taken to mean ‘anxiety’. Codes not in Chapter P were recorded as somatic
34 symptoms and diagnoses.
35
36
37
38
39
40
41
42
43
44

45 ***Prevalence of antidepressant prescription***

46 For each year, we calculated the number of patients (N) prescribed an antidepressant, SSRI or
47 TCA and whether the prescription was linked to a record of depression, anxiety or other
48 disorder (non-psychological/somatic). We recorded the number of patients with a prescription
49 per 1000 patient-years, linked to age and gender, within a certain year. These data allow for
50 extrapolation to the Dutch population based on a yearly weighted population at risk in the
51 NPCD, which varied annually from 1,087,395 to 1,641,806 patient-years.
52
53
54
55
56
57
58
59
60

Long-term use

To calculate the numbers of patients using prescriptions for several years, the data for different years were merged to give the number of patients with a recorded antidepressant prescription and diagnosis of depression in each of the study years (i.e., 2011, 2012, 2013, 2014 and 2015). Merging data for the five subsequent years resulted in a loss of cases, because the NIVEL database did not include all practices or patients in some years.

Statistical Analysis

We use multilevel logistic regression with patients clustered by general practice. The models were then analysed in MLwiN 2.30 (23), using with the options 'PQL' and 'second order' ('first order' was used if the model failed to converge), and 'constrained level one variance'.

Outcome measures

The main outcome measure was the number of patients (N) receiving at least four antidepressant prescriptions in 2011, as well as during each of the four subsequent years. We assumed that receiving four or more prescriptions in one year was consistent with chronic use, based on the common Dutch practice to prescribe antidepressants on repeat prescriptions for three-month periods.

Independent variables

At Level 1, we controlled for variation at the practice level. At Level 2, the patient level, we considered age in 2011, sex and diagnosis associated with the prescription (i.e., depression, anxiety or somatic problem)

RESULTS

The results about long-term antidepressants use are based on data for 326,025 patients (older

1
2
3 than 18 years) from 189 practices with valid prescription data for all five years of the study.

4
5 In 2011, antidepressants were prescribed to $\pm 71/1000$ registered patients aged ≥ 18 years.

6
7 About two-thirds of the prescriptions were for women and about one-third were for men.

8
9
10 30% of antidepressants were prescribed to, those aged 18–44 years, 45% to 45–64 years old
11
12 and 25% to those above 65 years. The distribution of the population at risk in 2011 was 43:
13
14 37: 20

15
16
17 Of the antidepressants prescribed, SSRIs and TCAs accounted for 52% and 28%,
18
19 respectively. Overall, 38% were prescribed for depression, 17% for anxiety, 20% for other
20
21 psychological diagnoses and 25% for somatic indications. SSRIs were more frequently
22
23 prescribed for depression (47%) and anxiety (23%), while TCAs tended to be prescribed
24
25 frequently for somatic disorders (44%) or other psychological disorders (21%). The main
26
27 somatic indications for TCAs were generalised pain (1.7%), lumbago (2.5%), low back pain
28
29 with radiation (2.5%), headache (2.7%), tension headache (2%), neuropathy (4.8%), sleeping
30
31 problems (4.1%) and type 2 diabetes mellitus (1.5%).
32
33

34
35
36 The data for the proportions of patients who continued to be prescribed antidepressants in
37
38 each year after 2011 are summarised in Figure 1 and Table 1.
39
40

41
42 Here figure 1
43

44
45 Of those who received at least four prescriptions in 2011, we found that 65% were still
46
47 receiving at least four prescriptions per year at two years and that 58% were still receiving
48
49 them at three years. However, only 42% of patients received at least four prescriptions of
50
51 antidepressants through each year from 2011 to 2015; by SSRI and TCA use, this was 38%
52
53 and 35%, respectively (Figure 1).
54

55
56 When we lower the threshold for chronic prescribing to at least one prescription a year, 65%
57
58 of patients receiving an AD prescription in 2011 kept receiving yearly at least one
59
60

prescription each year to 2015.

The odds for receiving antidepressants over five consecutive years based on patients' characteristics are shown in Table 1.

Table 1. Odds for Receiving an Antidepressant for Each Year between 2011 and 2015 after Receiving the First Prescription in 2011

Variable	Coefficient	SE	p-value	OR	95% CI
Sex (ref = male)					
Female	0.1400	0.0409	p < .001	1.15	1.06 1.25
Age (ref = 65+ years)					
19–44	-0.1161	0.0541	0.0320	0.89	0.80 0.99
45–64	0.2320	0.0476	p < .001	1.26	1.15 1.38
Disorder					
Anxiety (ref = no anxiety)	0.3196	0.0558	p < .001	1.38	1.23 1.54
Depression (ref = no depression)	0.3224	0.0488	p < .001	1.38	1.25 1.52
Somatic disorder (ref = no somatic disorder)	0.0153	0.0565	0.7864	1.02	0.91 1.13
Practice variance	6.763	0.8653			
ICC	0.67				
Constant	-4.2012	0.2276			

Abbreviations: CI, confidence interval; ICC, intra-class correlation coefficient; OR, odds ratio; SE, standard error

Specifically, the odds were higher for women than for men, for patients aged 45–65 years and for a diagnosis of anxiety or depression. However, there was substantial practice variation, meaning that the proportions were even larger in some practices but much smaller in others.

Tables 1 and 2 in the appendix show similar patterns for SSRIs and TCAs analysed separately, though with some exceptions. A diagnosis of anxiety, for example, did not affect long-term SSRI prescribing. Also, sex and older age affected long-term TCA prescribing, but indication did not.

DISCUSSION

Antidepressants were prescribed to almost 7% of the general practice population, aged 18 years and older, in this study. The main indication was for depression (38%), but anxiety (17%), other psychological disorders (20%) and non-psychological indications, mostly pain related (25%), were frequent. Interestingly, nearly half of the population (42%) received antidepressants throughout all five years of the study. The odds of long-term use were higher for women than for men, for those aged 45–64 years than for those aged ≥ 65 years and for those with psychological indications than for those with non-psychological indications. However, long-term prescribing habits varied markedly among practices.

Consistent with our results, Huijbregts et al. (17) reported that about 44% of antidepressant use was long term (defined as >15 months) based on one region in the Netherlands. In our larger nationwide population, with a much stricter definition of long-term use as five years of continuous receipt of four antidepressant prescriptions a year, 42% used antidepressants chronically. We also found the same risk factors for long-term use, with female sex, older age, and having a diagnosis of anxiety or depression being most important. However, in contrast with their data, we found that the group aged 45–64 years was at higher risk than the group aged ≥ 65 years.

Antidepressant medication use is a prominent topic of discussion in society. Opponents of their widespread use, such as Göttsche(24) and Greenberg(25), point to the lack of efficacy and the possible harms of long-term use. Risk of falls and fractures, upper gastro-intestinal bleed and epilepsy/seizures is increased among adult (20-64 year)AD users(26, 27). A higher risk for falls, attempted suicides, stroke, fracture and epilepsy is reported for older people, using AD(28). By contrast, proponents, such as Young and Crace(29), consider psychiatric

1
2
3 drugs to be as beneficial as other medical treatments and argue that concerns about long-term
4 use are overinflated. So, just how harmful is antidepressant use in the long term? We know
5 that antidepressant use is now on a large scale, partly for depression and anxiety, but also for
6 other psychological and non-psychological indications. This is important to understand
7 because antidepressants have only demonstrated slight effectiveness for the treatment of
8 depression and anxiety (30), and have unknown efficacy for those other disorders. Although
9 some patients will benefit from long-term use (31), at best, such use may be unhelpful to
10 many patients. Indeed, there is no conclusive evidence about the safety of antidepressants
11 over years, and Andrews et al. even claim that such use will generally do more harm than
12 good by disrupting key adaptive processes regulated by serotonin(32). Harm may also be
13 expected among older antidepressant users who are at risk of polypharmacy; antidepressant
14 use, for example, has an important negative impact on the Drug Burden Index, an indicator of
15 the cholinergic and sedative stress imposed by medication(33).

16
17 At first glance, general practitioners (GPs) might view antidepressant treatment as a good
18 initial therapy that is in the patient's interest. Despite the potential risks, and perhaps because
19 of the lack of clear evidence of harm, or reports of continuation problems, the option of long-
20 term use also remains acceptable (34). This is compounded by the fact that, when patients
21 have benefitted from relief of depressive symptoms, they often become reluctant to stop
22 therapy for fear of becoming depressed again(35). Therefore, large groups of patients with
23 single episodes of low severity depression, who probably received effective antidepressant
24 therapy in the beginning, progress to long-term use with less clearly defined benefits.

25
26 A way to prevent unnecessary long-term antidepressant use might be to institute annual
27 medication reviews. This issue is especially pertinent given that proactive medication reviews
28 have been reported to become increasingly sparse the longer antidepressants have been
29 prescribed, especially when not for an overt mental health reason(36).

1
2
3 The large practice variation that we found suggests long term AD prescribing to be a practice
4 policy, as has been reported in the case of antibiotics prescribing(37), where patient
5 characteristics could not explain the variation at practice level as well(38). Medication
6 reviews may reflect such a policy, possibly by routine consultations between GP and
7 pharmacist. As proven in other studies, medication reviews may be routine in some practices,
8 leading to reduced long-term antidepressant use, but may non-existent in other practices, with
9 opposing results (39). New initiatives, such as the introduction of tapering strips(40) or the
10 continuous monitoring of patients who discontinue antidepressants, could offer new insights
11 and help develop recommendations for GPs to help patients stop treatment when it is no
12 longer needed. Developing a consensus on how to discontinue antidepressants in general
13 practice could reduce practice variation and decrease the proportions of patients who continue
14 to take antidepressants beyond the required period for acute treatment and stabilization.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

30 **Limitations**

31
32 Although prescription data were available of 1–2 million patients, substantial numbers were
33 lost by merging prescription and morbidity data (providing us with the indication) and by
34 merging the data over several years (e.g., some practices were not part of the NPCD for the
35 full period and some patients were not registered for the full period). Therefore, the final
36 analyses were conducted on 326,025 cases from 189 practices. This final sample included
37 more patients aged >45 years and fewer men compared with the original database, so may
38 have not been truly representative of the Dutch population. Our definition of chronic
39 prescribing (at least four prescriptions in all years) is arbitrary. However, when we increase
40 the threshold to e.g. five prescriptions a year, chronic users having a repeat prescription each
41 three months would not be included. When we decrease the threshold to one prescription in
42 each of five years, the number of “chronic users” increases to 65%. Morbidity data were also
43 highly dependent on the coding registered by the GP. It is well known that GP variations in
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 diagnosis are large and that sensitivity can be suboptimal(41). However, the antidepressant
4 prescribing data were not dependent on the morbidity coding, which is a major strength.
5
6
7

8 **Conclusions**

9

10
11 Chronic antidepressant use was common in this cohort, with 42% of patients prescribed
12 antidepressants in 2011 continuing to use them at five years. Although the initial prescribing
13 of antidepressants might have become stable, patients continue to take their prescriptions for
14 many years, though with considerable variation in this trend between practices. It was
15 noteworthy that depression was not the main indication for antidepressant prescription, with a
16 quarter of prescriptions being for non-psychological indications and a fifth being for anxiety.
17 Therefore, we conclude that the high levels of antidepressant use can only partly be attributed
18 to depression, with the main issue appearing to be an increase in chronic usage after initial
19 prescribing. GPs and other prescribers should be aware of the risks of long-term
20 antidepressant use and ensure annual monitoring to reduce unnecessary prescribing.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: number of AD-users in 2011, who used AD chronically (≥ 4 prescription/year) in
the subsequent years.

Legend: ■: Total Antidepressants

■: SSRI

■: TCA

Acknowledgements

We thank Dr Robert Sykes (www.doctored.org.uk) for providing editorial services.

Author contributions

Peter Verhaak conceived the concept, analysed the data and wrote the paper. Derek de Beurs discussed the concept and commented on all drafts. Peter Spreeuwenberg performed the multilevel analysis and commented on all drafts.

Conflicts of interest

None

Funding

There is no funding to be reported. All authors are appointed by the Netherlands Institute of Health Services Research and had access to NIVEL Primary Care Database.

Transparency declaration

The lead author (PV) affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Ethical issues

This study has been approved according to the governance code of Nivel Primary Care Database, *under number NZR-00318.012*. European law allows the use of electronic health records for research purposes under certain conditions. According to this legislation, neither obtaining informed consent from patients nor approval by a medical ethics committee is obligatory for this type of observational studies containing no directly identifiable data. The study was conducted in accordance with the requirements of the Helsinki Declaration.

1
2
3 Patients in participating practices are informed about participation of the practice in NPCD
4
5 with an opportunity for opting out
6
7

8 **Data sharing statement**

9

10 We've got access to the anonymous database under condition that data will be used only for
11
12 the answering of the current research questions.
13
14

15 Researchers interested in our analyses can contact the first author or Dr Derek de Beurs
16
17 (second author; d.debeurs@nivel.nl) at NIVEL for possible secondary analysis of our dataset.
18
19
20
21
22

23 **References**


24

- 25 1. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative
26 efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major
27 depressive disorder: a systematic review and network meta-analysis. *The Lancet*.
28 2018;dx.doi.org/10.1016/50140-6736(17)32802-7.
- 29 2. Moore TJ, Mattison DR. Adult Utilization of Psychiatric Drugs and Differences by Sex, Age,
30 and Race. *JAMA Intern Med*. 2017;177(2):274-5.
- 31 3. Aarts N, Noordam R, Hofman A, Tiemeier H, Stricker BH, Visser LE. Self-reported indications
32 for antidepressant use in a population-based cohort of middle-aged and elderly. *Int J Clin Pharm*.
33 2016;38(5):1311-7.
- 34 4. Hanlon JT, Wang X, Castle NG, Stone RA, Handler SM, Semla TP, et al. Potential underuse,
35 overuse, and inappropriate use of antidepressants in older veteran nursing home residents. *Journal*
36 *of the American Geriatrics Society*. 2011;59(8):1412-20.
- 37 5. Harris T, Carey IM, Shah SM, DeWilde S, Cook DG. Antidepressant prescribing in older
38 primary care patients in community and care home settings in England and Wales. *J Am Med Dir*
39 *Assoc*. 2012;13(1):41-7.
- 40 6. Midlov P, Andersson M, Ostgren CJ, Molstad S. Depression and use of antidepressants in
41 Swedish nursing homes: a 12-month follow-up study. *International psychogeriatrics / IPA*.
42 2014;26(4):669-75.
- 43 7. Wong J, Motulsky A, Abrahamowicz M, Egual T, Buckeridge DL, Tamblyn R. Off-label
44 indications for antidepressants in primary care: descriptive study of prescriptions from an indication
45 based electronic prescribing system. *BMJ*. 2017;356:j603.
- 46 8. Weel-Baumgarten EMv, Gelderen MGv, Grundmeijer HGLM, Licht-Strunk E, Marwijk HWJv,
47 Rijswijk HCAMv, et al. NHG-Standaard Depressie (tweede herziening). *Huisarts & Wetenschap*.
48 2012;55(6):252-9.
- 49 9. Hassink-Franke L, Terluin B, Heest Fv, Hekman J, Marwijk Hv, Avendonk Mv. NHG-Standaard
50 Angst (tweede herziening). Utrecht: Nederlands Huisarts Genootschap, 2012.
- 51 10. Noordam R, Aarts N, Verhamme KM, Sturkenboom MC, Stricker BH, Visser LE. Prescription
52 and indication trends of antidepressant drugs in the Netherlands between 1996 and 2012: a dynamic
53 population-based study. *European journal of clinical pharmacology*. 2015;71(3):369-75.
- 54
55
56
57
58
59
60

11. Meijer WE, Heerdink ER, Leufkens HG, Herings RM, Egberts AC, Nolen WA. Incidence and determinants of long-term use of antidepressants. *European journal of clinical pharmacology*. 2004;60(1):57-61.
12. Sihvo S, Wahlbeck K, McCallum A, Sevon T, Arffman M, Haukka J, et al. Increase in the duration of antidepressant treatment from 1994 to 2003: a nationwide population-based study from Finland. *Pharmacoepidemiol Drug Saf*. 2010;19(11):1186-93.
13. Mojtabai R, Olfson M. National trends in long-term use of antidepressant medications: results from the U.S. National Health and Nutrition Examination Survey. *The Journal of clinical psychiatry*. 2014;75(2):169-77.
14. Mars B, Heron J, Kessler D, Davies NM, Martin RM, Thomas KH, et al. Influences on antidepressant prescribing trends in the UK: 1995-2011. *Soc Psychiatry Psychiatr Epidemiol*. 2017;52(2):193-200.
15. Moore M, Yuen HM, Dunn N, Mullee MA, Maskell J, Kendrick T. Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database. *BMJ*. 2009;339:b3999.
16. Lockhart P, Guthrie B. Trends in primary care antidepressant prescribing 1995-2007: a longitudinal population database analysis. *Br J Gen Pract*. 2011;61(590):e565-72.
17. Huijbregts KM, Hoogendoorn A, Slottje P, van Balkom A, Batelaan NM. Long-Term and Short-Term Antidepressant Use in General Practice: Data from a Large Cohort in the Netherlands. *Psychother Psychosom*. 2017;86(6):362-9.
18. Burton C, Anderson N, Wilde K, Simpson CR. Factors associated with duration of new antidepressant treatment: analysis of a large primary care database. *Br J Gen Pract*. 2012;62(595):e104-12.
19. Petty DR, House A, Knapp P, Raynor T, Zermansky A. Prevalence, duration and indications for prescribing of antidepressants in primary care. *Age Ageing*. 2006;35(5):523-6.
20. Read J, Gibson KL, Cartwright C. Are older people prescribed antidepressants on the basis of fewer symptoms of depression, and for longer periods of time? A survey of 1825 New Zealanders. *Australas J Ageing*. 2016;35(3):193-7.
21. Lu CY, Roughead E. New users of antidepressant medications: first episode duration and predictors of discontinuation. *European journal of clinical pharmacology*. 2012;68(1):65-71.
22. Lamberts H, Wood M. *International Classification of Primary Care*. Oxford: Oxford University Press; 1987 1987.
23. Rashbash J, Charlton C, Browne WJ, Healy M, Cameron B. *MLwiN Version 2.30*. Bristol 2009.
24. Gotzsche PC. Antidepressants are addictive and increase the risk of relapse. *BMJ*. 2016;352:i574.
25. Greenberg G. *Manufacturing depression: the secret history of a modern disease*. London: Bloomsbury; 2010.
26. Coupland C, Hill T, Morriss R, Moore M, Arthur A, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in people aged 20-64 years: cohort study using a primary care database. *BMC Med*. 2018;16(1):36.
27. Hill T, Coupland C, Morriss R, Arthur A, Moore M, Hippisley-Cox J. Antidepressant use and risk of epilepsy and seizures in people aged 20 to 64 years: cohort study using a primary care database. *BMC Psychiatry*. 2015;15:315.
28. Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. *BMJ*. 2011;343:d4551.
29. Gotzsche PC, Young AH, Crace J. Does long term use of psychiatric drugs cause more harm than good? *BMJ*. 2015;350:h2435.
30. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. *PLoS medicine*. 2008;5(2):e45.

- 1
- 2
- 3 31. Cuijpers P, van Straten A, van Oppen P, Andersson G. Are psychological and pharmacologic
- 4 interventions equally effective in the treatment of adult depressive disorders? A meta-analysis of
- 5 comparative studies. *The Journal of clinical psychiatry*. 2008;69(11):1675-85; quiz 839-41.
- 6
- 7 32. Andrews PW, Thomson JA, Jr., Amstadter A, Neale MC. Primum non nocere: an evolutionary
- 8 analysis of whether antidepressants do more harm than good. *Front Psychol*. 2012;3:117.
- 9
- 10 33. Mark TL, Joish VN, Hay JW, Sheehan DV, Johnston SS, Cao Z. Antidepressant use in geriatric
- 11 populations: the burden of side effects and interactions and their impact on adherence and costs.
- 12 *Am J Geriatr Psychiatry*. 2011;19(3):211-21.
- 13
- 14 34. Johnson CF, Williams B, MacGillivray SA, Dougall NJ, Maxwell M. 'Doing the right thing':
- 15 factors influencing GP prescribing of antidepressants and prescribed doses. *BMC Fam Pract*.
- 16 2017;18(1):72.
- 17
- 18 35. Bosman RC, Huijbregts KM, Verhaak PF, Ruhe HG, van Marwijk HW, van Balkom AJ, et al.
- 19 Long-term antidepressant use: a qualitative study on perspectives of patients and GPs in primary
- 20 care. *Br J Gen Pract*. 2016;66(651):e708-19.
- 21
- 22 36. Sinclair JE, Aucott LS, Lawton K, Reid IC, Cameron IM. The monitoring of longer term
- 23 prescriptions of antidepressants: observational study in a primary care setting. *Fam Pract*.
- 24 2014;31(4):419-26.
- 25
- 26 37. Kim JK, Chua ME, Ming JM, Braga LH, Smith GHH, Driver C, et al. Practice variation on use of
- 27 antibiotics: An international survey among pediatric urologists. *J Pediatr Urol*. 2018.
- 28
- 29 38. Manne M, Deshpande A, Hu B, Patel A, Taksler GB, Misra-Hebert AD, et al. Provider Variation
- 30 in Antibiotic Prescribing and Outcomes of Respiratory Tract Infections. *South Med J*.
- 31 2018;111(4):235-42.
- 32
- 33 39. Burton C, Cameron I, Anderson N. Explaining the variation between practices in the duration
- 34 of new antidepressant treatment: a database cohort study in primary care. *Br J Gen Pract*.
- 35 2015;65(631):e114-20.
- 36
- 37 40. Groot PC, Consensusgroup T. [Taperingstrips for paroxetine and venlafaxine]. *Tijdschr*
- 38 *Psychiatr*. 2013;55(10):789-94.
- 39
- 40 41. Carey M, Jones K, Meadows G, Sanson-Fisher R, D'Este C, Inder K, et al. Accuracy of general
- 41 practitioner unassisted detection of depression. *Aust N Z J Psychiatry*. 2014;48(6):571-8.
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Figure 1: number of AD-users in 2011, who used AD chronically (≥ 4 prescription/year) in the subsequent years



254x190mm (300 x 300 DPI)

Table 1. Odds for receiving an SSRI prescription each year between 2011 and 2015

Variable	Coefficient	Standard Error	p-value	Odds ratio	95% Confidence Interval	
Sex (male = ref)						
Female	0.1699	0.0576	0.0032	1.19	1.06	1.33
Age (65+ = ref)						
19–44	-0.1077	0.0767	0.1600	0.90	0.77	1.04
45–64	0.2582	0.0700	p < .001	1.29	1.13	1.49
Disorder						
Anxiety (no anxiety = ref)	0.0333	0.0771	0.6656	1.03	0.89	1.20
Depression (no depression = ref)	-0.1207	0.0698	0.0838	0.89	0.77	1.02
Somatic disorder (no somatic disorder = ref)	0.1537	0.0849	0.0703	1.17	0.99	1.38
Practice variance	4.711	0.626				
ICC	0.59					
Constant	-3.6397	0.2066				

Table 2. Odds for receiving a TCA prescription during each year between 2011 and 2015

Variable	Coefficient	Standard Error	p-value	Odds ratio	95% Confidence Interval	
Sex (male = ref)						
Female	0.2030	0.0917	0.0268	1.23	1.02	1.47
Age (65+ = ref)						
19–44	-0.6821	0.1300	p < .001	0.51	0.39	0.65
45–64	0.0393	0.0915	0.6673	1.04	0.87	1.24
Disorder						
Anxiety (no anxiety = ref)	0.2098	0.1387	0.1303	1.23	0.94	1.62
Depression (no depression = ref)	0.3797	0.1137	p < .001	1.46	1.17	1.83
Somatic disorder (no somatic disorder = ref)	-0.0631	0.1098	0.5654	0.94	0.76	1.16
Practice variance						
	2.763	0.4156				
ICC						
	0.46					
Constant						
	-3.6022	0.1936				

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Action
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	In title (p.1) and abstract (p.3)
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Done (p.3)
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Done (p. 5-7)
Objectives	3	State specific objectives, including any prespecified hypotheses	“we aimed to assess the extent of chronic antidepressant prescribing and to evaluate the determinants of that chronic prescribing.”(abstract, p.3)
Methods			
Study design	4	Present key elements of study design early in the paper	Design is presented in first paragraph of Method section (p.7)
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Not applicable
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	Not applicable
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Done: we defined outcome measures and independent variables (p.9)
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Done (p.8-9)
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	Not applicable
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Done (p.8-9)
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Done (p.9)
		(b) Describe any methods used to examine subgroups and interactions	Done (p.9)

		(c) Explain how missing data were addressed	Not applicable
		(d) If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Not applicable (p.7; 9; 14-15)
		(b) Give reasons for non-participation at each stage	Not applicable
		(c) Consider use of a flow diagram	Not applicable
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Done (p.10)
		(b) Indicate number of participants with missing data for each variable of interest	Not applicable
Outcome data	15*	Report numbers of outcome events or summary measures	Done (p.10)
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Done (p.10-12)
		(b) Report category boundaries when continuous variables were categorized	Not applicable
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not applicable
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	Done (p.12)
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Done (p.14-15)
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Done (p.15)
Generalisability	21	Discuss the generalisability (external validity) of the study results	Done (p.12, p.14)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Other information

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Not applicable
---------	----	---	----------------

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.